{
  "ticker": "COR",
  "content": "**Report Generated:** January 16, 2026  \n**Next Refresh:** April 17, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# Cencora, Inc. (COR) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nCencora, Inc. (NYSE: COR) is a global pharmaceutical sourcing and distribution services company that operates through two primary segments: U.S. Healthcare Solutions and International Healthcare Solutions. Founded by Emil P. Martini in 1947 and headquartered in Conshohocken, PA, the company has grown to become a leading global pharmaceutical solutions organization with 51,000+ employees worldwide.\n\nThe U.S. Healthcare Solutions segment distributes brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, and long-term care facilities. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services.\n\nCencora distributes pharmaceutical products to nearly one-third of the industry, and together with McKesson and Cardinal Health, holds over 90% share of the US pharmaceutical wholesale industry. The company is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $300 billion in annual revenue.\n\n## 2. Current Market Data\n\nThe current price of COR is $348.57 USD — it has increased by 1.09% in the past 24 hours. COR stock has risen by 1.72% compared to the previous week, the month change is a 0.26% rise, and over the last year Cencora, Inc. has showed a 46.65% increase. The current market capitalization is $68.62 billion, and the stock trades at a price-to-earnings (P/E) ratio of 43.44.\n\nThe stock's 52-week range extends from a low of $236.37 to a high of $377.54. Cencora's dividend yield was 0.70% in 2025, with a payout ratio of 27.63%, compared to 0.91% and 27.07% respectively in the prior year.\n\n## 3. Existing Products/Services\n\nCencora sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. The company also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health).\n\nKey service offerings include:\n- Pharmaceutical distribution across brand-name, specialty, and generic products\n- Plasma and blood products distribution\n- Vaccine distribution\n- Pharmacy management and staffing services\n- Supply management software\n- Clinical trial support and commercialization services\n- Data analytics and outcomes research\n- Third-party logistics (3PL) services\n\n## 4. Planned Products/Services/Projects\n\nCencora announced a significant $1 billion investment through 2030 to strengthen its U.S. distribution network, expand capacity, and increase resilience, aligning with the company's strategic focus on specialty pharmaceuticals and enhancing patient access. The company has also earmarked additional capital to expand U.S. drug distribution operations over the next five years, including plans for opening a second national distribution center.\n\nThe company is making elevated capital expenditure investments relative to recent years for U.S. supply chain infrastructure and IT investments to support digital transformation initiatives.\n\n## 5. Growth Strategy\n\nCencora's growth strategy focuses on \"making growth-oriented investments that support our pharmaceutical-centric strategy\" with an emphasis on strengthening solutions in specialty, as specialty physicians are increasingly seeking partners that can provide tools to streamline their operations and support cutting-edge treatments.\n\nThe company has identified three key growth priorities: leading with market leaders, strengthening its position in specialty pharmaceuticals, and enhancing patient access to pharmaceuticals. These priorities are supported by strategic drivers including customer-centricity with data and technology, growth-oriented investments, fostering a culture for industry-leading talent, and identifying capability and process improvements.\n\nCencora's long-term target for adjusted diluted EPS growth remains at 8% to 12%, which the company has been exceeding in recent quarters.\n\n## 6. Current and Potential Major Clients\n\nMajor client relationships include:\n- Walgreens Boots Alliance - though the company has announced plans to close a significant portion of its store locations over the next three years, the impact on Cencora is unclear as most volume from closed stores would likely shift to other Walgreens locations\n- Express Scripts manages pharmacy benefits for about 20 million Centene beneficiaries, with mail pharmacies supplied by Cencora and Cigna's CuraScript SD business\n- Publix (though this relationship recently shifted from Cencora to Cardinal Health)\n- Various hospital networks and health systems\n- Independent and chain retail pharmacies\n- Mail order pharmacies\n\n## 7. Financial Data & Performance\n\n**Fiscal 2025 Results:**\nRevenue increased 8.7 percent year-over-year to $80.7 billion in Q3 fiscal 2025. For the full fiscal year 2025, revenue increased 9.3 percent to $321.3 billion.\n\nAdjusted diluted EPS increased 19.8 percent to $4.00 in the fiscal third quarter from $3.34 in the prior year third quarter. For fiscal year 2025, adjusted diluted EPS increased 16.3 percent to $16.00.\n\nAdjusted operating income increased 15.8% to $4.2 billion for fiscal 2025, while adjusted diluted earnings per share grew 16.3% to $16.00. The company generated adjusted free cash flow of $3.0 billion and invested $668 million in capital expenditures during the fiscal year.\n\nEBITDA is $4.71 billion USD, with a current EBITDA margin of 1.46%.\n\n## 8. Headwinds & Tailwinds\n\n**Headwinds:**\nLoss of oncology customer following acquisition by a peer, creating a net headwind of 1% for the U.S. Healthcare Solutions segment in fiscal 2026\nGross profit margin pressure from increased sales volume of low-margin GLP-1 products and lower sales of commercial COVID-19 vaccines\nInternational Healthcare Solutions segment experiencing slower performance with ongoing softness in global specialty logistics business due to subdued clinical trial activity\nGovernment policies such as those enacted by the Inflation Reduction Act affecting drug pricing and reimbursement\nOngoing litigation concerning the opioid crisis, with the company involved in a settlement payout of up to $6.1 billion over 18 years\n\n**Tailwinds:**\nSignificant tailwinds from GLP-1s (diabetes and weight-loss drugs) showing impressive double-digit year-over-year growth\nStrong utilization trends and growth in specialty pharmaceuticals\nAnticipated growth from biosimilars pipeline, especially in Part B biosimilars\nResilience of business amidst ongoing market challenges, highlighting the diversified nature of Cencora's operations\n\n## 9. Market Shares\n\nAs of Q2 2025, Cencora secured a 34.56% market share within the Pharmacy Services & Retail Drugstore Industry, competing directly with McKesson Corporation at 41.21% and Cardinal Health at 24.24%. Cencora's market share decreased from 34.80% to 34.56% between Q1 and Q2 2025 while McKesson gained.\n\nThe U.S. pharmaceutical wholesale distribution industry is an extremely concentrated oligopoly dominated by three firms: McKesson Corporation, Cencora, and Cardinal Health, which collectively control well over 90% of the market by revenue. These three companies make up 95% of the overall US drug distribution market, and no major acquisitions among competitors have occurred over the last five years.\n\n## 10. Comparison to Competitors\n\nCencora (formerly AmerisourceBergen), with revenues surpassing $293.96 billion in 2024, stands as a significant competitor to McKesson, leveraging extensive distribution networks and pricing strategies to compete. McKesson secured the OptumRx contract, a move that previously generated approximately $32 billion for Cardinal Health in fiscal 2023.\n\nThe pharmaceutical distribution industry operates as a highly concentrated oligopoly with McKesson, Cencora, and Cardinal Health controlling over 90% of the U.S. market, providing competitive advantages and high barriers to entry while enabling consistent profits and steady growth for the dominant players.\n\nFinancially, the Big Three wholesalers—McKesson, Cencora, and Cardinal Health—are doing well, with revenues and operating incomes rising at near-double-digit rates.\n\n## 11. Partnerships, Mergers and Acquisitions\n\n**Major Recent Acquisitions:**\n\n**OneOncology:** In December 2025, Cencora announced it will acquire the majority of outstanding equity interests in OneOncology for approximately $3.6 billion, valuing the OneOncology enterprise at $7.4 billion, with total cash consideration of approximately $5.0 billion including debt retirement. OneOncology operates a network of independent community oncology practices with 31 partner practices of approximately 1,800 providers across 365 nationwide care sites.\n\n**Retina Consultants of America (RCA):** In late 2024, Cencora acquired RCA for $4.6 billion, a management services organization that operates a large network of retina specialists. RCA's nearly 300 retina specialists across 23 states provide high-quality care to patients with physicians conducting over 2 million visits annually.\n\n**Historical Acquisitions:** In 2021, Cencora sealed a deal with Walgreens Boots Alliance, acquiring the majority of Alliance Healthcare business for approximately $6.5 billion, which included $6.275 billion in cash and 2 million shares of Cencora common stock.\n\n## 12. Recent Developments\n\n**December 2025:** Cencora announced accelerated acquisition of OneOncology's majority equity interests from TPG\n\n**November 2025:** Cencora reported Q4 fiscal 2025 results with revenue of $83.7 billion, hosting a conference call on November 5, 2025\n\n**November 2025:** Cencora announced a fiscal 2026 annualized dividend of $2.40 per share, representing a 9% increase year-over-year\n\n**October 2025:** Cencora's Board appointed Lead Independent Director D. Mark Durcan as Chairman of the Board, effective October 1, 2025, succeeding Steven H. Collis\n\n**Fiscal 2026 Guidance:** Cencora provided guidance for revenue growth of 5% to 7% and adjusted operating income growth of 8% to 10%, with adjusted diluted earnings per share expected to be in the range of $17.45 to $17.75\n\n## 13. AI Investment Rating & Fair Value Assessment\n\n**Analyst Consensus:** The 13 analysts that cover Cencora stock have a consensus rating of \"Buy\" and an average price target of $354.85, which forecasts a 1.74% increase in the stock price over the next year. Based on analysis of 30 Wall Street analysts, COR has a median price target of $397.50, with the highest target at $417.00 and lowest at $300.00, with 11 Buy ratings, 4 Hold ratings, and 1 Sell ratings.\n\n**Recent Price Target Changes:**\n- Evercore ISI raised price target to $420 from $400\n- UBS raised target to $415, TD Cowen increased to $400\n- Multiple firms have raised targets, while BofA lowered to $360 on valuation concerns\n\n**Valuation Metrics:** Cencora trades at a P/E ratio of 41.52 and a high PEG ratio of 7.41, indicating the stock is trading at a premium relative to its growth rate. Morningstar indicates COR is trading at a 594% premium to fair value estimates.\n\n**Investment Rating: 7.2/10**\n\n**Rationale for Rating:**\n- **Strengths:** Dominant market position in essential healthcare distribution, strong financial performance with consistent double-digit earnings growth, strategic acquisitions in high-growth specialty segments, robust free cash flow generation\n- **Concerns:** High current valuation metrics, regulatory and litigation risks, dependency on key client relationships, margin pressure from product mix changes\n- **Moderate Risk Assessment:** While the business fundamentals are strong, the elevated valuation suggests limited upside at current levels\n\n**Fair Value Estimate: $320-$340**\n\nBased on the company's strong market position, consistent earnings growth trajectory, and strategic positioning in specialty pharmaceuticals, but accounting for the current premium valuation and various operational headwinds, a fair value range of $320-$340 appears appropriate for growth-oriented investors with moderate risk tolerance. This represents approximately 8-15% downside from current levels around $348, suggesting investors may want to wait for a better entry point or dollar-cost average into the position.",
  "generated_date": "2026-01-16T07:09:13.878409",
  "next_refresh_date": "2026-04-17T07:09:13.878409",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.4049547,
  "tokens": {
    "input": 189,
    "output": 4703,
    "cache_creation": 71036,
    "cache_read": 224859
  },
  "tldr_summary": "Cencora (COR) is a global pharmaceutical distribution and services company that sources and distributes pharmaceuticals, medical products, and healthcare solutions to a wide range of providers and pharmacies. The company holds a dominant market position, controlling approximately 34.56% of the pharmacy services market alongside McKesson and Cardinal Health, with over $321 billion in annual revenue.\n\nKey strategic priorities include expanding specialty pharmaceutical services, investing $1 billion in U.S. distribution network infrastructure through 2030, and pursuing targeted acquisitions like OneOncology ($3.6 billion) and Retina Consultants of America ($4.6 billion). The company demonstrates consistent financial performance with 16.3% year-over-year earnings growth and strong tailwinds from GLP-1 drug distribution and biosimilars market expansion.\n\nWith an AI investment rating of 7.2/10, Cencora is rated a moderate \"Buy\" with a fair value estimate of $320-$340, reflecting strong fundamentals tempered by current premium valuation."
}